Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2019

View Archived Issues

Brain activity predicts SSRI success

Anxious mitochondria shut down under stress

NIDA grant supports Kinoxis' development of KNX-100 for opioid withdrawal

Vaccinex presents interim results from CLASSICAL-Lung study of pepinemab plus avelumab

Tavapadon results in improvement of motor symptoms in subjects with early-stage PD

Biallelic ZNF142-null mutations as new gene biomarkers in patients with generalized dystonia

FDA clears IND application for TPX-0046

FDA completes review of IND for mRNA-3927

Idera initiates ILLUMINATE-206 study of tilsotolimod in combination with nivolumab and ipilimumab

Vertex and Ribometrix collaborate on discovery and development of RNA-targeted therapeutics

Positive findings from phase IIb study with orvepitant in RUCC

Brain tumors, metastases form synapses with neurons

Phase II results for TAS-115 for the treatment of IPF presented

FDA approves Invokana for use in patients with type 2 diabetes and diabetic kidney disease

Annexon reports phase Ib data on ANX-005 in Guillain-Barre syndrome

Phase III RESTORE-IMI 2 trial of Recarbrio in HABP/VABP meets primary endpoint

Chinese investigators patent CDK4 and/or CDK6 inhibitors

Janssen presents free fatty acid FFA1 and/or FFA4 receptor agonists

FDA issues complete response letter for PT-010 for COPD

AnaptysBio reports phase II interim data on ANB-019 in generalized pustular psoriasis

U.S. investigators identify new apoptosis inducers for cancer

NantKwest studies PD-L1 t-haNK for locally advanced or metastatic solid cancers in phase I

Chinese researchers describe new HIV antivirals

University of California patents compounds for periodontal disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...